HOME ȸ»ç¼Ò°³ ½ÃÀÛÆäÀÌÁö·Î Áñ°Üã±âÃß°¡ ±âÀÚȸ¿ø½Åû
[¸ð¹ÙÀϸðµå] ·Î±×ÀΠȸ¿ø°¡ÀÔ
2024³â05¿ù15ÀÏwed
±â»çÃÖÁ¾ÆíÁýÀÏ: 2024-05-14 18:10:27
´º½ºÈ¨ > µ¿Á¤
2023³â10¿ù04ÀÏ 11½Ã39ºÐ
±ÛÀÚÅ©±â ±â»ç³»¿ë À̸ÞÀϺ¸³»±â ´º½ºÇÁ¸°Æ®Çϱ⠴º½º½ºÅ©·¦Çϱâ
¼­¿ï¼º¸ð Ç÷¾×º´¿ø ±³¼öÁø, '´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ °¢Á¾ »ó' ¼ö»ó

[º¸°ÇŸÀÓÁî] °¡Å縯´ëÇб³ ¼­¿ï¼º¸ðº´¿ø Ç÷¾×º´¿ø ¹Î±âÁØ(»çÁø ÁÂ), °û´ëÈÆ ±³¼ö(Áß), ±è°¡¿µ ÀÓ»ó°­»ç(Ç÷¾×³»°ú) µî ±³¼öÁøÀÌ ÃÖ±Ù ºÎ»ê º¤½ºÄÚ¿¡¼­ ¿­¸° '2023 ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ ±¹Á¦Çмú´ëȸ(ICBMT 2023)'¿¡¼­ ¿ì¼ö ±¸¿¬ ¹ßÇ¥»ó°ú ¿ì¼ö Æ÷½ºÅÍ ¹ßÇ¥»ó µî °¢Á¾ »óÀ» ¼ö»óÇÔÀ¸·Î½á ÇмúÀû À§»óÀ» ³ô¿´´Ù.

¹Î ±³¼ö´Â 'Autologous stem cell mobilization using high-dose methotrexate and cytarabine combined chemotherapy plus granulocyte colony-stimulating factor for patients with high-risk or relapsed lymphomas (°íÀ§Ç豺 ¶Ç´Â Àç¹ßÇÑ ¸²ÇÁÁ¾ ȯÀÚ¿¡¼­ °í¿ë·® ¸ÞÅäÆ®·º¼¼ÀÌÆ®¿Í ½ÃŸ¶óºó º´¿ë È­Çпä¹ý°ú °ú¸³±¸ Áý¶ô ÀÚ±Ø ÀÎÀÚ¸¦ »ç¿ëÇÑ ÀÚ°¡Á¶Ç÷¸ð¼¼Æ÷ äÁý)'¶ó´Â ÁÖÁ¦¸¦ ¹ßÇ¥, ¿¬±¸¼º°ú¸¦ ÀÎÁ¤¹Þ¾Ò´Ù.

°û ±³¼ö´Â 'Comparative Analysis Of Graft Sources In Young AML Patients Receiving Matched Sibling Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation: Is Peripheral Blood Graft Really A Superior Choice Than Bone Marrow Graft?(°í°­µµ Àüóġ¸¦ ¹Þ´Â ÀþÀº ÇüÁ¦°£ ÀÌ½Ä ±Þ¼º °ñ¼ö¼º ¹éÇ÷º´ ȯÀÚ¿¡¼­ °ñ¼ö Á¶Ç÷¸ð¼¼Æ÷¿Í ¸»ÃÊ Á¶Ç÷¸ð¼¼Æ÷ °£ÀÇ ºñ±³)'¶ó´Â ÁÖÁ¦¸¦ ¹ßÇ¥, Àç¹ß·üÀÇ Â÷ÀÌ´Â ¾øÀ¸¸é¼­ ³·Àº À̽ÄÆí´ë ¼÷ÁÖº´ ¹ß»ý·ü·Î ¿øÀÎÀÓÀ» È®ÀνÃÄ×´Ù.

±è°¡¿µ ÀÓ»ó°­»ç´Â 'Correlation between clinical diagnosis and histopathological findings of liver dysfunction after allogeneic-HSCT(Á¶Ç÷¸ð¼¼Æ÷ ÀÌ½Ä ÈÄ °£¼öÄ¡ ÀÌ»óÀ¸·Î °£Á¶Á÷°Ë»ç ½ÃÇàÇÑ È¯ÀÚÀÇ ÀÓ»óÁø´Ü°ú º´¸® ¼Ò°ß ´ëÁ¶)'¶ó´Â ÁÖÁ¦¸¦ ¹ßÇ¥, ¿øÀÎÀÌ ºÒ¸íÈ®ÇÑ È²´Þ ¼öÄ¡°¡ ´Üµ¶ »ó½ÂÇÑ »ç·ÊµéÀÇ Á¶Á÷¼Ò°ßÀÌ ´Ù¾çÇÏ°Ô È®ÀεƴÙ.

Ç÷¾×º´¿ø ÀÌÀç¿í ±³¼ö(»çÁø ¿ì, ¼Ò¾Æû¼Ò³â°ú), ³²È£Çü ÀÓ»ó°­»ç(Ç÷¾×³»°ú)´Â ¿ì¼ö Æ÷½ºÅÍ ¹ßÇ¥»óÀ» ¼ö»óÇß´Ù.

ÀÌ ±³¼ö´Â 'Sequential chemotherapy and myeloablative conditioning-based HSCT for pediatric patients with relapsed/refractory acute leukemia'¶ó´Â ÁÖÁ¦·Î, Àç¹ß ¶Ç´Â ºÒÀÀ¼º ¼Ò¾Æ ±Þ¼º¹éÇ÷º´ ȯÀÚ¿¡¼­ Ç×¾ÏÄ¡·á Á÷ÈÄ ¿¬¼ÓÀûÀ¸·Î °­·ÂÇÑ Àüóġ¸¦ Æ÷ÇÔÇÑ µ¿Á¾Á¶Ç÷¸ð¼¼Æ÷À̽ÄÀ» ½ÃÇàÇÏ´Â °ÍÀÇ Ä¡·á ¼ºÀû ¿¬±¸¸¦ ¹ßÇ¥, ¿¹ÈÄ°¡ ÁÁÁö ¾ÊÀº Àç¹ß ¶Ç´Â ºÒÀÀ¼º ¼Ò¾Æ ±Þ¼º¹éÇ÷º´ ȯÀÚÀÇ ÀÌ½Ä ¼ºÀûÀ» Çâ»ó½Ãų ¼ö ÀÖ´ÂÁö È®ÀÎÇÏ·Á´Â ÁÖ¿ä ¿¬±¸ ¸ñÀûÀ» ´Þ¼ºÇß´Ù.

³²È£Çü ÀÓ»ó°­»ç´Â 'Early clinical outcomes of phase 2 trial: dose-reduced ATG and PTCY combination for GVHD prophylaxis in adult patients with acute lymphoblastic leukemia treated with unrelated or haploidentical donor hematopoietic stem cell transplantation'¶ó´Â ÁÖÁ¦¸¦ ¹ßÇ¥Çß´Ù.

°ü·Ã±â»ç°¡ ¾ø½À´Ï´Ù
´º½º½ºÅ©·¦Çϱâ
Á¶ÇöÁø (bktimes@naver.com) ±âÀÚ 
À̱âÀÚÀÇ ´Ù¸¥´º½ºº¸±â
µ¿Á¤¼½¼Ç ¸ñ·ÏÀ¸·Î
ÀüÀ±»ó ÀÎÇϴ뺴¿ø ±³¼ö, ...
µ¿»êÀÇ·á¿ø ±ÇÅÂÂù ±³¼ö »õ...
¾È¼öÁø ±³¼ö, 'Á¦26ȸ °úÇÐ...
¿µ³²ÀÇ´ë ±èÁ¤Èñ ±³¼ö Çѱ¹...
±èµ¿±Ô ±³¼ö, ¾Æ½Ã¾Æ°¨¸¶³ª...
´ÙÀ½±â»ç : °¡Å縯´ë ¿©Àǵµ¼º¸ðº´¿ø Á¶Á¤±â ±³¼ö, ´ëÇÑôÃ߽Űæ¿Ü°úÇÐȸ ȸÀå ÃëÀÓ (2023-10-04 13:45:33)
ÀÌÀü±â»ç : °Ç±¹´ëº´¿ø ÀüÈ«ÁØ ±³¼ö, '´ëÇѼö¸éÀÇÇÐȸ Çмú»ó' ¼ö»ó (2023-10-04 11:38:17)
º´¿ø°è, "°è...
º´¿ø°è, "°è¹¦³â...
Á¦¾à¡¤°Ç½Ä 12°³...
´ë¿õÁ¦¾à, ¿Ã »ó¹Ý±â '¿µ¾÷ ºÎ...
º¸·É, ¿ÃÇØ »ó¹Ý±â '¿µ¾÷Á÷ ½Å...
°Çº¸°ø´Ü, ¼Ò¼Ó±â°ü '¼­¿ï¿ä¾ç...
¼ºÀåÇÏ°íÇ ´ç½Å, "Áö±Ý ´ë¿õ,...
º¸·ÉÁ¦¾à, ¿Ã »ó¹Ý±â '¿µ¾÷Á÷ ...
³í¹®) In Vivo Reactive Astrocyte Imaging in Patien...
ȸ»ç¼Ò°³ °³ÀÎÁ¤º¸º¸È£Á¤Ã¥ ÀÌ¿ë¾à°ü À̸ÞÀÏÁÖ¼Ò¹«´Ü¼öÁý°ÅºÎ ¾Ë¸³´Ï´Ù º¸µµÀÚ·á ±â»çÁ¦º¸ Á¤±â±¸µ¶